Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1983 Nov;80(3):503–509. doi: 10.1111/j.1476-5381.1983.tb10722.x

Inflammatory actions of platelet activating factor (Pafacether) in guinea-pig skin.

J Morley, C P Page, W Paul
PMCID: PMC2045011  PMID: 6685552

Abstract

Cutaneous responses to synthetic platelet activating factor (Paf-acether) have been studied in guinea-pigs by means of radioisotopic marker techniques. Intradermal injection of Paf-acether elicited increased plasma protein extravasation (IPPE) (0.2-200 pmol/site), platelet accumulation (PA) (20-200 pmol/site) and red blood cell accumulation (RBCA) (200 pmol/site), whereas lyso-Paf (up to 2 nmol/site) was inactive in all these respects. Following intradermal injection, the IPPE responses to Paf-acether (2 and 20 pmol/site) were complete within 15 and 30 min respectively, although in response to 200 pmol/site, IPPE was detectable up to 1.5 h. The PA and RBCA responses to Paf-acether (200 pmol/site) were complete within 1 h. IPPE induced by Paf-acether (3 pmol/site) was potentiated by concomitant intradermal injection of a cutaneous vasodilator prostaglandin E2 (PGE2, 1 nmol/site) and inhibited by the beta-adrenoceptor agonist, isoprenaline (4.5 nmol/site) or the alpha-adrenoceptor agonist, phenylephrine (6 nmol/site). Such observations are consistent with Paf-acether effecting increased vessel wall permeability. Intradermal injection of PGE1 (3 nmol/site) significantly reduced PA in response to Paf-acether (200 pmol/site), whilst significantly enhancing IPPE. This dissociation of increased vascular permeability from PA is consistent with Paf-acether eliciting IPPE via a platelet-independent mechanism. These results indicate that a direct effect on vessel wall permeability contributes to the inflammatory response to Paf-acether in guinea-pig skin. It is suggested that Paf-acether is a potential mediator of allergy and inflammation.

Full text

PDF
503

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Beets J. L., Paul W. Actions of locally administered adrenoceptor agonists on increased plasma protein extravasation and blood flow in guinea-pig skin. Br J Pharmacol. 1980 Nov;70(3):461–467. doi: 10.1111/j.1476-5381.1980.tb08724.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Benveniste J., Henson P. M., Cochrane C. G. Leukocyte-dependent histamine release from rabbit platelets. The role of IgE, basophils, and a platelet-activating factor. J Exp Med. 1972 Dec 1;136(6):1356–1377. doi: 10.1084/jem.136.6.1356. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Benveniste J., Tencé M., Varenne P., Bidault J., Boullet C., Polonsky J. Semi-synthèse et structure proposée du facteur activant les plaquettes (P.A.F.): PAF-acether, un alkyl ether analogue de la lysophosphatidylcholine. C R Seances Acad Sci D. 1979 Nov 26;289(14):1037–1040. [PubMed] [Google Scholar]
  4. Bonnet J., Loiseau A. M., Orvoen M., Bessin P. Platelet-activating factor acether (PAF-acether) involvement in acute inflammatory and pain processes. Agents Actions. 1981 Dec;11(6-7):559–562. doi: 10.1007/BF01978740. [DOI] [PubMed] [Google Scholar]
  5. Demopoulos C. A., Pinckard R. N., Hanahan D. J. Platelet-activating factor. Evidence for 1-O-alkyl-2-acetyl-sn-glyceryl-3-phosphorylcholine as the active component (a new class of lipid chemical mediators). J Biol Chem. 1979 Oct 10;254(19):9355–9358. [PubMed] [Google Scholar]
  6. Humphrey D. M., McManus L. M., Satouchi K., Hanahan D. J., Pinckard R. N. Vasoactive properties of acetyl glyceryl ether phosphorylcholine and analogues. Lab Invest. 1982 Apr;46(4):422–427. [PubMed] [Google Scholar]
  7. Page C. P., Paul W., Morley J. An in vivo model for studying platelet aggregation and disaggregation. Thromb Haemost. 1982 Jun 28;47(3):210–213. [PubMed] [Google Scholar]
  8. Page C. P., Paul W., Morley J. Continuous monitoring of plasma protein extravasation and cell accumulation in vivo. Br J Dermatol. 1983 Jul;109 (Suppl 25):103–105. [PubMed] [Google Scholar]
  9. Stimler N. P., Bloor C. M., Hugli T. E., Wykle R. L., McCall C. E., O'Flaherty J. T. Anaphylactic actions of platelet-activating factor. Am J Pathol. 1981 Oct;105(1):64–69. [PMC free article] [PubMed] [Google Scholar]
  10. Vargaftig B. B., Chignard M., Benveniste J., Lefort J., Wal F. Background and present status of research on platelet-activating factor (PAF-acether). Ann N Y Acad Sci. 1981;370:119–137. doi: 10.1111/j.1749-6632.1981.tb29727.x. [DOI] [PubMed] [Google Scholar]
  11. Vargaftig B. B., Ferreira S. H. Blockade of the inflammatory effects of platelet-activating factor by cyclo-oxygenase inhibitors. Braz J Med Biol Res. 1981 Jul;14(2-3):187–189. [PubMed] [Google Scholar]
  12. Wedmore C. V., Williams T. J. Control of vascular permeability by polymorphonuclear leukocytes in inflammation. Nature. 1981 Feb 19;289(5799):646–650. doi: 10.1038/289646a0. [DOI] [PubMed] [Google Scholar]
  13. Williams T. J., Peck M. J. Role of prostaglandin-mediated vasodilatation in inflammation. Nature. 1977 Dec 8;270(5637):530–532. doi: 10.1038/270530a0. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES